Skip to main content

Advertisement

Table 8 12-year return-on-investment (ROI) for early-treatment (per patient screened) for ranibizumab therapy for neovascular AMD

From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

12-year costs (US 2012 real dollars) associated with early-treatment vs. late-treatment ranibizumab therapy Genetic screening/monitoring costs expended (%) per patient screened Negative societal costs returned for genetic costs expended (% = percent of total costs returned) Net final cost 12-year financial return-on-investment (ROI) Diminution in usual cost due to costs returned from genetic testing
Overall costs $2205 (100 %) (−$7500) (100 %) (−$5295) 240 % 340 %
Medicare (Medicare pays 80 % of Part B costs) $1559 (70.7 %) (−$548) (7.3 %) $1011 −65 %a 35 %
Medicaid $84 (3.8 %) (−$53) (0.7 %) $31 −37 %a 63 %
Commercial insurance (Medi-gap policies covering 20 % of approved Medicare cost) $348 (15.8 %) (−$83) (1.1 %) $266 −78 %a 22 %
Commercial insurance (under age 65 years) $174 (7.9 %) (−$53) (0.7 %) $122 −76 % 24 %
Patients (NB. Healthcare insurance costs are not included) $40 (1.8 %) (−$6765) (90.2 %) (−$6725) 16,945 % 17,045 %
  1. Note the direct ophthalmic medical costs associated with ranibizumab therapy are the same for the early-treatment and late-treatment ranibizumab therapy cohorts, thus not integrated. Costs with parentheses () indicate negative costs that accrue against the direct ophthalmic medical costs expended for ranibizumab therapy
  2. AMD age-related macular degeneration